Compare Adaptive Biotechnologies Corp (ADPT) vs IAC/Interactivecorp (PPLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs IAC/Interactivecorp — how do they compare? Adaptive Biotechnologies Corp trades at $25.69 (market cap $4.05B), while IAC/Interactivecorp trades at $40.21 (market cap $3.03B). The key difference: Adaptive Biotechnologies Corp is the larger of the two by market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, IAC/Interactivecorp nearer its low. Which is the better fit depends on your goals.
| ADPT | PPLI | |
|---|---|---|
Market Cap | $4.05B | $3.03B |
Sector | Health | Media |
52-Week High | $25.45 | $47.62 |
52-Week Low | $12.30 | $31.52 |
Enterprise Value | $4.12B | $3.34B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $24.93, up 5.64% in 24 hours and near its 52-week high. The stock shows bullish technical momentum with improving fundamentals as revenue grew 55% year-over-year to $277M in 2025 while net losses narrowed significantly from -$159M to -$59M. The company's strategic shift to focus on its profitable MRD diagnostics business through a planned separation of Immune Medicine operations has driven investor optimism.
Outlook remains cautiously optimistic as ADPT transitions to a pure-play MRD company with strong gross margins exceeding 75%. While analyst consensus favors Buy ratings (65%), persistent net losses and high valuation multiples (P/S 12.6x, P/B 27.8x) present risks. The $25.50 price target suggests limited upside from current levels amid execution risks.
People Incorporated (PPLI) trades at $41.58, down 3.17% amid bearish technical signals despite strong Q2 2026 earnings beat. The company shows mixed fundamentals with attractive valuation ratios (P/E 7.04, P/B 0.61) but volatile profitability trends. Recent news highlights digital revenue growth, corporate restructuring, and MGM investment gains, while institutional activity shows mixed positioning with Amundi increasing stake by 397.4% in Q2 2026.
PPLI presents a value opportunity with deep discount to analyst consensus target of $60.50 (45% upside), though investors face execution risks from restructuring and inconsistent earnings history. The stock's near-term direction hinges on successful asset monetization and sustained digital growth against backdrop of negative cash flow trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About IAC/Interactivecorp
IAC Inc is an Internet media company with segments that include Angi (47% of total revenue), Dotdash (10%), search (24%), and emerging and other (19%). The firm spun off the narrow-moat dating app provider Match Group in second-quarter 2020 and the no-moat video software provider Vimeo in second-quarter 2021.
Read more on PPLI →
